Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A, Swedish CLL Group

Open source

DOI
10.3324/haematol.2018.198820
Published
2019 May
Container
Haematologica
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2018.198820,
  title = {Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.},
  author = {Winqvist M and Andersson PO and Asklid A and Karlsson K and Karlsson C and Lauri B and Lundin J and Mattsson M and Norin S and Sandstedt A and Rosenquist R and Späth F and Hansson L and Österborg A and Swedish CLL Group},
  year = {2019},
  journal = {Haematologica},
  doi = {10.3324/haematol.2018.198820},
  url = {https://doi.org/10.3324/haematol.2018.198820}
}

RIS

TY  - JOUR
TI  - Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
AU  - Winqvist M
AU  - Andersson PO
AU  - Asklid A
AU  - Karlsson K
AU  - Karlsson C
AU  - Lauri B
AU  - Lundin J
AU  - Mattsson M
AU  - Norin S
AU  - Sandstedt A
AU  - Rosenquist R
AU  - Späth F
AU  - Hansson L
AU  - Österborg A
AU  - Swedish CLL Group
PY  - 2019
JO  - Haematologica
DO  - 10.3324/haematol.2018.198820
UR  - https://doi.org/10.3324/haematol.2018.198820
ER  - 

APA

M, W., PO, A., A, A., K, K., C, K., B, L., J, L., M, M., S, N., A, S., R, R., F, S., L, H., A, Ö., & Group, S. C. (2019). Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.. Haematologica. https://doi.org/10.3324/haematol.2018.198820

Source records